Infectious Disease

The study found that measles antibody levels during 2 long-term follow-ups fell lower than those observed before receipt of the third MMR dose.

The study findings on enhanced immunity from a third mRNA-1273 dose and specific population benefits will help build effective public health policy, authors say.

The intranasal delivery and live attenuated form of CoviLiv may strengthen immune response and vaccine acceptance and uptake in populations and regions where both are low.

Researchers say findings demonstrate the capacity to use an existing influenza vaccine effectiveness network to study a large immunocompromised population.

IDWeek 2023: In a large cohort of people living with HIV, those switching from oral ART to long acting CAB+RPV were more than 4x as likely to adhere to the regimen.

Approved for persons with HIV with undetectable VL, CAB+RPV LA may also be appropriate for those with VL ≥50 copies when the therapy is initiated, according to new findings.

IDWeek 2023: Adolescents expressed a preference for a combination vaccine covering serogroups A, B, C, W, Y of invasive meningococcal disease, reported researchers.

COVID-19, influenza, and RSV will be the topics of a different types of sessions examining the history, new diagnostics, prevention, and future treatments during IDWeek 2023.

Findings underscore the persistence of disparities in meningococcal vaccination coverage in the US, particularly for vaccination against serogroup B.

IDWeek 2023: Leading physician scientists will headline plenary sessions and named lectureships on topics ranging from antibiotic stewardship to artificial intelligence.

Your daily dose of the clinical news you may have missed.

IDWeek 2023: Imagine an intriguing hot topic in infectious disease and you'll find a session or 2 where you can learn more and then choose the next topic, rinse, and repeat.

A 2-question quiz on the ACIP's recommendations on the new COVID-19 monovalent vaccines that provide protection from currently circulating strains.

The Novavax COVID-19 vaccine is refreshed with 2023-2024 formula targeting the XBB.1.5 strain.

Results from a new study of Medicare beneficiaries admitted for an emergency general surgery show the odds of 30-day readmission was 67% lower for those with follow-up visit.

Your daily dose of the clinical news you may have missed.

Less than one-quarter of US adults surveyed said they would "definitely" get the shot while 33% stated they would "definitely not" get the new vaccine.

Members of the ACIP voted on Friday to recommend Pfizer’s maternal bivalent RSVpreF vaccine to protect newborns from severe RSV illness.

Meta-analysis: Among persons with symptoms of long COVID, respiratory and exercise training were effective but pooled information on safety was "uncertain, imprecise."

Your daily dose of the clinical news you may have missed.

Your daily dose of clinical news you may have missed.

As COVID-19 hospitalizations increase at the opening of the respiratory virus season, the first "seasonal" vaccine against the virus is ready for roll-out, says the FDA.

Parent's stigmatizing beliefs about the HPV vaccine may keep them from communicating openly with teens' clinicians, creating barriers to getting shots in arms.

"Keep the vaccination conversation going this year, even though your patients, and probably you, too, have grown tired of the issues and your team is worn out."

Vaccination against SARS-CoV-2 may decrease the symptoms of post-COVID conditions, such as abdominal pain and weakness, according to new study.

Findings from a recent study show a broad spectrum of possible clinical manifestations of IRD following SARS-CoV-2 infection or COVID-19 vaccination.

The expanded labeling for the antiviral against COVID-19 indicates no dose adjustment is required for persons across all stages of liver disease.

A large study of hospitalized children with SARS-CoV-2 infection found that disease severity varied by age over the course of the COVID-19 pandemic.

The USPSTF particularly emphasizes effective communication with patients, including adherence support and calls for reducing barriers to PrEP for racial, ethnic, and other minority groups.

The FDA approved Abrysvo for use in pregnant individuals to prevent LRTD and severe LRTD caused by RSV in infants from birth through 6 months of age.